Publicaciones en colaboración con investigadores/as de Novo Nordisk (4)

2015

  1. Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy

    Diabetes, Obesity and Metabolism

2012

  1. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): A phase 3, randomised, open-label, treat-to-target non-inferiority trial

    The Lancet, Vol. 379, Núm. 9825, pp. 1498-1507

2007

  1. The societal costs of intracerebral hemorrhage in Spain

    European Journal of Neurology, Vol. 14, Núm. 5, pp. 556-562

1999

  1. Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals

    Environmental Health Perspectives, Vol. 107, Núm. SUPPL. 1, pp. 89-108